Haloperidol and reduced haloperidol plasma levels in selected schizophrenic patients

Larry Ereshefsky; Chester M. Davis; Charles A. Harrington; Michael W. Jann; Jeffrey L. Browning; Stephen R. Saklad; Neil R. Burch

doi:10.1097/00004714-198406000-00005

Haloperidol and reduced haloperidol plasma levels in selected schizophrenic patients

Larry Ereshefsky, Chester M. Davis, Charles A. Harrington, Michael W. Jann, Jeffrey L. Browning, Stephen R. Saklad, Neil R. Burch

Research output: Contribution to journal › Article › peer-review

93 Scopus citations

Abstract

The first measurements of haloperidol (HL) and its reduced metabolite hydroxyhaloperidol (RH) in plasma versus clinical response in five chronic schizophrenic patients are reported. HL and RH were measured by a radioimmunoassay with a low coefficient of variation. Patients were selected based on poor response or the need for high dosage and were rated with the Clinical Global Impression Scale. Daily HL dosage range was 0.5 to 1.5 mg/kg. HL plasma concentrations ranged from 14 to 98 ng/ml. RH plasma concentrations ranged from 10 to 319 ng/ml. Four patients did not respond to HL therapy; two of these improved dramatically when switched to fluphenazine. The four nonresponding patients had higher RH than HL concentrations. RH seems to be present in plasma in significant concentrations, and further investigation of the relationships of RH and HL plasma levels versus response is needed.

Original language	English
Pages (from-to)	138-142
Number of pages	5
Journal	Journal of Clinical Psychopharmacology
Volume	4
Issue number	3
DOIs	https://doi.org/10.1097/00004714-198406000-00005
State	Published - Jun 1984

Access to Document

10.1097/00004714-198406000-00005

Cite this

@article{487e6121325f42dfb7764cda82fe4a8e,

title = "Haloperidol and reduced haloperidol plasma levels in selected schizophrenic patients",

abstract = "The first measurements of haloperidol (HL) and its reduced metabolite hydroxyhaloperidol (RH) in plasma versus clinical response in five chronic schizophrenic patients are reported. HL and RH were measured by a radioimmunoassay with a low coefficient of variation. Patients were selected based on poor response or the need for high dosage and were rated with the Clinical Global Impression Scale. Daily HL dosage range was 0.5 to 1.5 mg/kg. HL plasma concentrations ranged from 14 to 98 ng/ml. RH plasma concentrations ranged from 10 to 319 ng/ml. Four patients did not respond to HL therapy; two of these improved dramatically when switched to fluphenazine. The four nonresponding patients had higher RH than HL concentrations. RH seems to be present in plasma in significant concentrations, and further investigation of the relationships of RH and HL plasma levels versus response is needed.",

author = "Larry Ereshefsky and Davis, {Chester M.} and Harrington, {Charles A.} and Jann, {Michael W.} and Browning, {Jeffrey L.} and Saklad, {Stephen R.} and Burch, {Neil R.}",

year = "1984",

month = jun,

doi = "10.1097/00004714-198406000-00005",

language = "English",

volume = "4",

pages = "138--142",

journal = "Journal of Clinical Psychopharmacology",

issn = "0271-0749",

publisher = "Lippincott Williams and Wilkins Ltd.",

number = "3",

}

TY - JOUR

T1 - Haloperidol and reduced haloperidol plasma levels in selected schizophrenic patients

AU - Ereshefsky, Larry

AU - Davis, Chester M.

AU - Harrington, Charles A.

AU - Jann, Michael W.

AU - Browning, Jeffrey L.

AU - Saklad, Stephen R.

AU - Burch, Neil R.

PY - 1984/6

Y1 - 1984/6

N2 - The first measurements of haloperidol (HL) and its reduced metabolite hydroxyhaloperidol (RH) in plasma versus clinical response in five chronic schizophrenic patients are reported. HL and RH were measured by a radioimmunoassay with a low coefficient of variation. Patients were selected based on poor response or the need for high dosage and were rated with the Clinical Global Impression Scale. Daily HL dosage range was 0.5 to 1.5 mg/kg. HL plasma concentrations ranged from 14 to 98 ng/ml. RH plasma concentrations ranged from 10 to 319 ng/ml. Four patients did not respond to HL therapy; two of these improved dramatically when switched to fluphenazine. The four nonresponding patients had higher RH than HL concentrations. RH seems to be present in plasma in significant concentrations, and further investigation of the relationships of RH and HL plasma levels versus response is needed.

AB - The first measurements of haloperidol (HL) and its reduced metabolite hydroxyhaloperidol (RH) in plasma versus clinical response in five chronic schizophrenic patients are reported. HL and RH were measured by a radioimmunoassay with a low coefficient of variation. Patients were selected based on poor response or the need for high dosage and were rated with the Clinical Global Impression Scale. Daily HL dosage range was 0.5 to 1.5 mg/kg. HL plasma concentrations ranged from 14 to 98 ng/ml. RH plasma concentrations ranged from 10 to 319 ng/ml. Four patients did not respond to HL therapy; two of these improved dramatically when switched to fluphenazine. The four nonresponding patients had higher RH than HL concentrations. RH seems to be present in plasma in significant concentrations, and further investigation of the relationships of RH and HL plasma levels versus response is needed.

UR - http://www.scopus.com/inward/record.url?scp=0021136699&partnerID=8YFLogxK

U2 - 10.1097/00004714-198406000-00005

DO - 10.1097/00004714-198406000-00005

M3 - Article

C2 - 6736273

AN - SCOPUS:0021136699

SN - 0271-0749

VL - 4

SP - 138

EP - 142

JO - Journal of Clinical Psychopharmacology

JF - Journal of Clinical Psychopharmacology

IS - 3

ER -

Haloperidol and reduced haloperidol plasma levels in selected schizophrenic patients

Abstract

Access to Document

Other files and links

Fingerprint

Cite this